Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Fajac

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
ERJ Open Research|January 5, 2022
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in EuropeAndreas Jung, Annalisa Orenti, Fiona Dunlevy, et al.
The European Respiratory Journal|February 16, 2023
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del <i>CFTR</i> variantPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
ERJ Open Research|January 5, 2022
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in EuropeAndreas Jung, Annalisa Orenti, Fiona Dunlevy, et al.
The European Respiratory Journal|February 16, 2023
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del <i>CFTR</i> variantPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, et al.
Pageof 8